Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Everett Harris & Co. CA

Everett Harris & Co. CA lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,453,089 shares of the company’s stock after buying an additional 14,475 shares during the period. Novo Nordisk A/S makes up approximately 7.0% of Everett Harris & Co. CA’s holdings, making the stock its 5th largest position. Everett Harris & Co. CA owned approximately 0.14% of Novo Nordisk A/S worth $555,095,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC increased its holdings in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $86,000. Talbot Financial LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $4,066,000. Finally, Zions Bancorporation N.A. increased its holdings in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 1.2 %

Shares of NVO opened at $84.36 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $93.97 and a 200-day simple moving average of $113.62. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The stock has a market cap of $378.56 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.